MDCO Wins 2nd Suit Over Angiomax Patent Extension
A federal judge has ruled that the U.S. Patent and Trademark Office should find that The Medicines Co. filed its application to extend a patent for anti-coagulant Angiomax in a timely...To view the full article, register now.
Already a subscriber? Click here to view full article